Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis

Vertex Pharmaceuticals announced new interim data from its ALYFTREK study, showing recovery of pancreatic function in some children aged 2 to 5 with cystic fibrosis, enabling them to discontinue pancreatic enzyme replacement therapy. This finding challenges the previous belief that pancreatic exocrine insufficiency in these patients was irreversible. The data was presented at the North American Cystic Fibrosis Conference.